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counseling and testing for hereditary
cancer risk in young adult women:
Facilitating autonomy and informed
decision making is key”Thank you to Professor Peshkin and colleagues for their thoughtful
letter (Peshkin et al., 2015). They have provided a thorough outline
for consideration of genetic testing of women ages 18–20. We
completely agree that a one size ﬁts all approach does not do justice
to the particular needs of each individual. The speciﬁc gene, family
history and the circumstances of each woman should be a factor.
Some syndromes such as Lynch, Peutz Jeghers or ovarian small cell
carcinoma can occur in youngerwomen and testingmay be appropriate
at a younger age.
Our emphasis is on informed consent and that testing women for
these genes should be offered in adulthood. We have used the recom-
mendation of age of 21 as a timewhenwomen are transitioning to inde-
pendent living and autonomy, and a time when the results would be
delivered closer to an age where they will be actionable. Relevant
management decisions in BRCA mutation carriers are unlikely to occur
between age 18 and 21, but if these decisions were dependent on the
knowledge of gene status then we would agree that testing would be
appropriate. Such examples would be for prenatal diagnosis. We
would presume that it is unlikely that an 18 year old would base a
decision to use oral contraceptives on her gene status. Decisions
regarding surveillance and risk reducing surgery for BRCA1 and BRCA2
are not recommended until age 25 unless in special circumstance of
family history.
Studies on disclosing BRCA test results to adolescents suggest that
communication is more robust in mothers who have received negative
or uninformative results rather than positive results (Tercyak et al.,
2013). Studies of psychological impact and distress caused by geneticDOIs of original article: http://dx.doi.org/10.1016/j.ygyno.2014.09.009, http://dx.doi.org/
10.1016/j.gore.2015.10.001.
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2352-5789/© 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NCtesting have not looked at this young age group and we should be
cautious not to extrapolate from studies of cohorts with the majority
of women undergoing testing were over the age of 45 (Schwartz et al.,
2002). The updated American Society of Clinical Oncology guidelines
have emphasized informed consent over age (Robson et al., 2010). We
agree that there is paucity of data on the impact of testing in very
young women (ages 18–20) and in light of the lack of data, our intent
was to recommend age 21 not as a strict cut off but as a reasonable
age to consider testing given the lack of clinical relevance and impact
of earlier testing.
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